A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies
Joseph P. Eder(Yale Cancer Center), Patricia LoRusso(Yale Cancer Center), Thomas A. Puchalski(Dana-Farber Cancer Institute), David P. Ryan(East Carolina University), J. D. Rothermel(Novartis (Switzerland)), Angela Campbell(Novartis (Switzerland)), Jeffrey W. Clark(Massachusetts General Hospital), Jeffrey G. Supko(Harvard University), Pamela DeLuca(Wayne State University), Antoinette Wozniak(Wayne State University), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre)
Cited by 32
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k